** Another False Alarm **
On the bright side.... Population of Malaysia is 20 million+
--------------------------------------------------------
Trinity Biotech Distributor Wins Government HIV Screening Tender in Malaysia
BusinessWire, Thursday, February 26, 1998 at 08:23
DUBLIN, Ireland--(BW HealthWire)--February 26, 1998--TRINITY
BIOTECH PLC (NASDAQ:TRIBY) is pleased to announce the successful
acquisition of a Malaysian government tender by BIO-LINK Sendirian
Berhad for the Uni-Gold(tm) HIV rapid test.
The Uni-Gold(tm) HIV rapid test will be utilized in a government
HIV screening program throughout Malaysia. Following local trials and
evaluations, the Uni-Gold(tm) HIV product was chosen above competitive
products for this program.
The simplicity of this test, which uses whole blood as a sample,
was a critical factor in meeting the government's requirements and
needs.
Ronan O'Caoimh, CEO of Trinity Biotech, commented, "The
Uni-Gold(tm) HIV test is ideally suited to rapid, near patient testing
-- without the use of instrumentation or complex laboratory procedures
-- as it utilizes whole blood in a simple one-step procedure to give
results in less than 10 minutes. We are pleased to see continuing
expansion of our global distribution of this successful product."
Trinity Biotech develops, manufactures and markets diagnostic
products that address all three segments of the diagnostic market: (1)
rapid tests for the emerging point-of-care (POC) market, (2)
simplified tests for the self-test (OTC) market, and (3) microtitre
plate kits for the clinical laboratory market. The company's products
are sold in over 65 countries around the world.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995. The statements that are not historical facts
contained in this release are forward-looking statements that involve
risks and uncertainties, including but not limited to, the results of
research and development efforts, the effect of regulation by the
United States Food and Drug Administration and other agencies, the
impact of competitive products, product development, commercialization
and technological difficulties, and other risks detailed in the
Company's Securities and Exchange Commission filings.
CONTACT: TRINITY BIOTECH PLC
Jonathan O'Connell
Chief Financial Officer
(800) 603-8076 |
